Canadian fertilizer maker and farm products retailer Agrium Inc. (NYSE:AGU) reported on Tuesday that it anticipates its Q2 earnings to be at or near the top of its estimate range due to higher prices for several of its wholesale fertilizer products.
The Calgary-based firm has estimates earnings a share from continuing operations at $4.18 to $4.78, excluding one-time items. Analysts had been forecasting average earnings of $4.57 per share, according to Thomson Reuters.
CEO Mike Wilson stated in a statement late on Monday that outlook remains very optimistic, supported by the strong global grain prices and a balanced-to-tight international nutrient supply demand situation.
Moving readers toward the broader market, let’s consider percentage change in stocks prices of other stocks in the similar sector who contribute major role in the market that includes Potash Corp./Saskatchewan (USA) (NYSE:POT) surged +2.82%, Rentech, Inc. (NYSEAMEX:RTK) fell -0.58%, Monsanto Company (NYSE:MON) which increased +1.45% and CF Industries Holdings, Inc. (NYSE:CF) moved up +1.39%.
Agrium Inc. (USA) (NYSE:AGU) stock’s trade at beginning with a price of $79.06 and throughout the trading session climbed at a high of $82.81 other than when day-trade ended the stock finally advanced 4.85% to $82.52.
The stock is going forward its 52 week low with 37.64% and logging behind from its 52 week high price with -11.44%. AGU last month stock price volatility remained 2.63%.
AGU stock institutional ownership remained 68.66%.In its share capital AGU has 158.02 million outstanding shares among them 157.50 million shares have been floated in market exchange.
Company’s beta coefficient included 1.63. Beta factors measures the amount of market risk associated with market trade.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL